Research Staff/Technician

hong kong university logo queen mary hosipital logo

Dr. Stephanie S. LIU (劉皙博士)

Research Officer
MD (Sun Yat Sen); MSc (McGill); PhD (HK)
  • location
    L7-47, Laboratory Block, FOMB, 21 Sassoon Road, Pokfulam, Hong Kong
  • telephone
    (852) 2819 9368
  • facsimile
    (852) 2816 1947
  • HKU Scholars Hub
Research Interests
  • Functional and epigenetic study of oncogenes and tumor suppressor genes (involved in apoptotic pathway) in response to radio and chemotherapies in gynecological tumors.
  • Genetic epidemiological study including human papillomavirus (HPV) infection in cervical precancerous lesions and carcinomas, risk association study of single nucleotide polymorphisms (SNPs) of oncogenes and tumor suppressor genes in gynecological tumors.

Publications

2018
  • Zhou W., Sun W., Yung M.H., Dai S., Cai Y., Chen C.W., Meng Y., Lee J.B., Braisted J.C., Xu Y., Southall N.T., Shinn P., Huang X., Song Z., Chen X., Kai Y., Cai X., Li Z., Hao Q., Cheung A.N.Y., Ngan H.Y.S., Liu S., Barak S., Hao J., Dai Z., Tzatsos A., Peng W., Pei H., Han Z., Chan D.W., Zheng W. and Zhu W., Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance, Oncogene. 2018. http://dx.doi.org/10.1038/s41388-018-0238-8 (Publication No. : 284933)

  • Sun J., Cai X., Yung M.H., Zhou W., Li J., Zhang Y., Li Z., Liu S., Cheung A.N.Y., Ngan H.Y.S., Li Y., Dai Z., Kai Y., Tzatsos A., Peng W., Chan D.W. and Zhu W., miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer, Oncogene. Springer Nature Limited, 2018. http://dx.doi.org/10.1038/s41388-018-0459-x (Publication No. : 290017)

  • Liu S., Chan K.K.L., Chu K.H., Wei N., Lau S.K., Ngu S.F., Chu M.Y.M., Tse K.Y., Ip P.C.P., Ng E.K.O., Cheung A.N.Y. and Ngan H.Y.S., Oncogenic microRNA signature for early diagnosis of cervical intraepithelial neoplasia and cancer, 2018. http://dx.doi.org/10.1002/1878-0261.12383(Publication No. : 294143)

2017
  • Chan K.K.L., Siu K.Y., JIANG Y., WANG J., Wang Y., Leung T.H.Y., Liu S., Cheung A.N.Y. and Ngan H.Y.S., Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis, BMC Cancer. 2017.

  • Mak CS, Yung MMH, Hui LMN, Leung LL, Liang R, Chen KM, Liu SS, Qin Y, Leung THY,  Lee KF, Chan KKL, Ngan HYS and Chan DW*  Dysregulation of miR-141/KLF12/Sp1/survivin signaling promotes anoikis resistance in ovarian cancer metastatic progression. Mol Cancer 2017 16(1):1-17.

  • Mak CS, Yung MM, Hui LM, Leung LL, Liang R, Chen K, Liu SS, Qin Y, Leung TH, Lee KF, Chan KK, Ngan HY, Chan DW. MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis. Mol Cancer. 2017 Jan 17;16(1):11. doi: 10.1186/s12943-017-0582-2.

2015
  • Leung TW, Liu S, Leung CY, Chu MM, Cheung ANY and Ngan HYS. HPV 16 E2 binding sites 1 and 2 become more methylated than E2 binding site 4 during cervical carcinogenesis. J Med Virol 2015, 2015 Jun;87(6):1022-33.

  • Chu MYM, Liu S, Tam KF, Ip PCP, Cheung ANY and Ngan HYS. The Significance of Mismatch Repair Deficiency in Young Patients With Endometrial Cancer. Int J Gynecol Pathology 2015, 34: 403-410.

2014
  • Chan KKL, Leung TH, Chan DW, Wei N, Lau GT, Liu SS, Siu MK, and Ngan HY.  Targeting estrogen receptor subtypes in ovarian cancer. J. Endocrinol2014 221(2):325-36.

  • Liu MX, Siu MMK, Liu SS, JW Yam and Ngan HYS*and Chan DW*. Epigenetic silencing of miR-199b-5p is associated with chemoresistance of ovarian cancer through activation of JAG-1/NOTCH signaling cascade. Oncotarget 20145(4):94-958. (* co-corresponding author)

  • Liu X, Siu KY, Liu S, Yam JWP, Ngan HYS and Chan DW. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. Oncotarget 2014, 5: 944–958.

  • Chan KKL, Leung THY, Chan DW, Wei N, Lau TY, Liu S, Siu KY and Ngan HYS. Targeting estrogen receptor subtypes (ERalpha and ERbeta) with selective ER modulators in ovarian cancer. Journal of Endocrinology 2014, 221: 325-336.

2012
  • Wei N, Liu SS, Chan KK, Ngan HY. Tumour suppressive function and modulation of programmed cell death 4 (PDCD4) in ovarian cancer. PLoS One. 2012;7(1):e30311. [PubMed]

  • Wong OG, Lo CK, Chow JN, Tsun OK, Szeto E, Liu SS, Ngan HY, Cheung AN. Comparison of the GenoFlow human papillomavirus (HPV) test and the Linear Array assay for HPV screening in an Asian population. J Clin Microbiol. 2012 May;50(5):1691-7. [PubMed]

  • Zhang P, Liu SS, Ngan HY. TAp73-mediated the activation of c-Jun N-terminal kinase enhances cellular chemosensitivity to cisplatin in ovarian cancer cells. PLoS One. 2012;7(8):e42985. [PubMed]

2011
  • Liu SS, Chan KY, Leung RC, Chan KK, Tam KF, Luk MH, Lo SS, Fong DY, Cheung AN, Lin ZQ, Ngan HY. Prevalence and risk factors of Human Papillomavirus (HPV) infection in southern Chinese women - a population-based study. PLoS One. 2011 May 3;6(5):e19244.

2010
  • Liu S, Leung CY, Chan KKL, Cheung ANY, Ngan HYS. Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay by comparison with Roche Linear Array HPV genotyping assay. Journal of Clinical Microbiology. 2010;48:758-64. (Publication No. : 176805) 

2008
  • Chan KK, Wei N, Liu SS, Xiao-Yun L, Cheung AN, Ngan HY. Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Obstet Gynecol. 2008 Jan;111(1):144-51. [PubMed]